Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

被引：0
|
作者：
Matthias Lang
Thomas Longerich
Chrysanthi Anamaterou
机构：
[1] University Hospital Heidelberg,Department of General
[2] University Hospital Heidelberg,, Visceral
[3] University of Heidelberg, and Transplant Surgery
来源：
Thyroid Research | / 16卷
关键词：
Anaplastic thyroid carcinoma; Vemurafenib; BRAF-inhibitor; Adjuvant targeted therapy; BRAF(V600E)-mutation; Review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation
    Mey, Ulrich J. M.
    Renner, Christoph
    von Moos, Roger
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 890 - 893
  • [32] An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis
    Behnagh, Arman Karimi
    Eghbali, Maryam
    Abdolmaleki, Fereshteh
    Ghadikolaei, Omolbanin Asadi
    Asl, Parisa Rezazadeh
    Afsharpad, Mandana
    Cheraghi, Sara
    Honardoost, Maryam
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (07) : 1496 - 1507
  • [33] Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E-Mutated Multiple Myeloma
    Sharman, J. P.
    Chmielecki, J.
    Morosini, D.
    Palmer, G. A.
    Ross, J. S.
    Stephens, P. J.
    Stafl, J.
    Miller, V. A.
    Ali, S. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : E161 - E163
  • [34] Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review
    Weng, Shanshan
    Zhang, Ding
    Yang, Mengyuan
    Wang, Liuhong
    Yuan, Ying
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (12): : 1787 - 1791
  • [35] Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
    Nowara, Elzbieta
    Huszno, Joanna
    Slomian, Grzegorz
    Nieckula, Jaroslaw
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2016, 33 (01): : 52 - 56
  • [36] BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
    Ros, Javier
    Baraibar, Iosune
    Sardo, Emilia
    Mulet, Nuria
    Salva, Francesc
    Argiles, Guillem
    Martini, Giulia
    Ciardiello, Davide
    Cuadra, Jose Luis
    Tabernero, Josep
    Elez, Elena
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [37] Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
    Goodall, Megan L.
    Wang, Tong
    Martin, Katie R.
    Kortus, Matthew G.
    Kauffman, Audra L.
    Trent, Jeffrey M.
    Gately, Stephen
    MacKeigan, Jeffrey P.
    AUTOPHAGY, 2014, 10 (06) : 1120 - 1136
  • [38] EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines
    Jia, Yongsheng
    Zhang, Cuicui
    Hu, Chuanxiang
    Yu, Yang
    Zheng, Xiangqian
    Li, Yigong
    Gao, Ming
    ONCOLOGY LETTERS, 2018, 15 (05) : 6763 - 6769
  • [39] Management of V600E and V600K BRAF-Mutant Melanoma
    Alexandra M. Haugh
    Douglas B. Johnson
    Current Treatment Options in Oncology, 2019, 20
  • [40] Management of V600E and V600K BRAF-Mutant Melanoma
    Haugh, Alexandra M.
    Johnson, Douglas B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
12345